Literature DB >> 28903360

Variants in the CXCL12 gene was associated with coronary artery disease susceptibility in Chinese Han population.

Junbo Zhang1, Huijun Ma2, Jie Gao3, Shu Kong4, Jiangtao You5, Ying Sheng1.   

Abstract

BACKGROUND: Coronary artery disease (CAD) is one of the most serious diseases all around the world. Previous studies have shown the function of CXCL12 in the process of atherosclerosis. The aim of this research is to examine whether variants of CXCL12 contribute to CAD.
MATERIALS AND METHODS: To examine whether variants of CXCL12 contribute to CAD, we selected 6 single nucleotide polymorphisms (SNPs) of CXCL12, and genotyped by Sequenom MassARRAY technology in 597 CAD patients and 685 healthy control. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression adjusted for age and gender. We also analysis the differences in continuous variables among the subjects with three genotypes of related genes were assessed using the ANOVA.
RESULTS: We found significant differences in apoB concentrations with rs1065297 and rs10793538 different genotype. In the allele model, rs1065297, rs266089 and rs10793538 in CXCL12 gene associated with the risk of CAD. Stratified according to gender, rs266089 and rs2839693 in CXCL12 gene were associated with the risk of CAD in men, while rs1065297 and rs10793538 in CXCL12 gene were associated with the risk of CAD in women. Stratified according to age, rs197452 decreased the risk of CAD in less than 50 years old group. While in more than 50 years old group, not find significant results. Haplotype analysis shown that haplotype "TGCC" in the block increased CAD risk (OR=1.26, 95%CI: 1.00-1.58, p=0.046).
CONCLUSION: This study provides an evidence for polymorphism of CXCL12 gene associated with CAD development in Chinese Han population.

Entities:  

Keywords:  CXCL12; case-control study; coronary heart disease; gene polymorphisms

Year:  2017        PMID: 28903360      PMCID: PMC5589599          DOI: 10.18632/oncotarget.17171

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Coronary artery disease (CAD), also named as coronary heart disease (CHD) or ischaemic heart disease (IHD), has become one of the most common cause of morbidity and mortality in cardiovascular diseases (CVDs) all around the world, especially in the industrial countries [1]. Coronary heart disease (CHD) is caused by obstruction of epicardial coronary artery that supplies blood and oxygen to the heart. Multiple factors, such as lifestyle and environmental factors, play critical roles in the occurrence and progression of CHD. The characteristic pathological changes of CAD is atherosclerosis that results from the endothelial injury or functional disorder, which is triggered by the abnormal accumulation of lipoproteins in the intima [2]. Plenty of cells such as T cells, dendritic cells, neutrophils and macrophages are also involved into the process of the disease. Traditional environmental risk factor for CAD contains tobacco smoking, hypertension, diabetes or hyperglycemia, hyperlipidemia especially high levels of LDL and obesity or overweight [3]. There is a growing worldwide awareness of that heritable factors play an important role in the progress of atherosclerosis [4] and relatively a great many genome-wide association studies (GWAS) have confirmed the effect of genes in CAD [5-7]. Atherosclerosis is actually a chronic inflammatory reaction in blood vessels and includes two remarkable steps, foam cell formation and smooth muscle cell recruitment. Chemokine (C-X-C motif) ligand 12 (CXCL12), also called stromal cell-derived factor-1 (SDF-1), is one of the members of CXC chemokine family [8] and mostly known for its crucial role in the accumulation of smooth muscle progenitor cells (SPCs) [9]. It will trigger MAPK and PI3K signal pathway [10] by binding to a G protein-coupled receptor, CXCR4, and contribute to macrophage migration which results from lipid accumulation especially low-density lipoprotein (LDL) [11]. Additionally, it is identified that different single nucleotide polymorphisms (SNPs) of CXCL12 participates in various disease such as neck and head squamous cell carcinoma [12], myelodysplastic syndromes [13], multiple sclerosis [14], etc. Here, we choose six SNPs (rs1065297, rs1801157, rs266089, rs197452, rs2839693 and rs10793538) of CXCL12 to explore which SNPs are associated with the risk of CAD.

RESULTS

After all the experiments and data compilation, 597 cases (376 males and 221 females) and 685 controls (385 males and 300 females) were included in the final analysis. As listed in Table 1, the mean age of cases is 61.44 while the control group is 48.59. The p value of age and sex were less than 0.001 and 0.014, respectively. Clinical and biochemical index of information in CAD patients in the Table 1, including ALT, AST, GGT, TP, GLU, TG, TC, HDL, LDL, apoA, apoB, LP(a), ect.
Table 1

Basic information of case and control groups

CaseControlp
femalemalefemalemale
<5541124214184
≥5518025286101
total5976850.014
Mean age61.4448.59p <0.001
ALT (U/L)31.15±2.11
AST (U/L)36.41±2.93
GGT (U/L)44.65±3.77
TP(g/L)66.39±0.3
GLU (mmol/L)6.34±0.11
TG (mmol/L)1.8±0.07
TC (mmol/L)4.09±0.06
HDL-C (mmol/L)1.13±0.01
LDL-C (mmol/L)1.92±0.04
APOA1 (g/L)1.26±0.01
APOB (g/L)1±0.02
Lp(a) (mg/L)239.2±12.14

ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma-glutamyl transpeptidase, TP: total protein, GLU: glucose, TG: triglyceride, TC: total cholesterol, HDL: high-density lipoprotein, LDL: low-density lipoprotein, apoA: apolipoprotein A, apoB: apolipoprotein B, LP(a): lipoprotein.

p <0.05, statistical significance.

ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma-glutamyl transpeptidase, TP: total protein, GLU: glucose, TG: triglyceride, TC: total cholesterol, HDL: high-density lipoprotein, LDL: low-density lipoprotein, apoA: apolipoprotein A, apoB: apolipoprotein B, LP(a): lipoprotein. p <0.05, statistical significance. The basic characteristics of the study subjects stratified by different genotype are shown in Table 2. We found significant differences in apoB concentrations with rs1065297 and rs10793538 different genotype. For rs1065297, the mean serum apoB concentration was 1.03 for the GG genotype (highest), 0.76 for the GA genotype (lowest), 1.01 for AA genotype (p = 0.003). For rs10793538, the mean serum apoB concentration of TT, TA and AA is 1.03, 0.76, and 1.01 respectively.
Table 2

Characteristics of the subjects with 3 different genotypes

SNPGenotypep
rs1065297GGGAAA
LDL-Csample size127402
Mean±std2.431.53±0.651.94±0.840.036
apoBsample size127401
Mean±std1.030.76±0.311.01±0.370.003
rs1801157CCCTTT
TPsample size27214822
Mean±std67.03±6.3365.44±6.2664.83±6.470.023
rs10793538TTTAAA
apoBsample size126402
Mean±std1.030.76±0321.01±0.370.004

p <0.05, statistical significance.

p <0.05, statistical significance. The allele information including MAF, HWE, OR etc. were demonstrated in Table 3. In the allele model, rs1065297, rs266089 and rs10793538 in CXCL12 gene associated with the risk of CAD. Among them CXCL12 rs1065297 and rs10793538 decreased CAD risk (rs1065297: OR=0.64, 95%CI: 0.46-0.90, p=0.010; rs10793538: OR=0.67, 95%CI: 0.47-0.93, p=0.016). Rs266089 in CXCL12 gene increased the risk of CAD (OR=1.23, 95%CI: 1.00-1.51, p=0.046). Stratified according to gender, in the allele model, rs266089 and rs2839693 in CXCL12 gene were associated with the risk of CAD in men, while rs1065297 and rs10793538 in CXCL12 gene were associated with the risk of CAD in women.
Table 3

Basic SNPs in CXCL12 gene summary of all study participants

SNPBase/ChangeMAFHWEpTotalMaleFemale
CaseControlOR(95%CI)pOR(95%CI)pOR(95%CI)p
rs1065297G/A0.0460.070.040.64(0.46-0.90)0.010.74(0.48-1.14)0.1660.51(0.29-0.89)0.017
rs1801157T/C0.2170.210.6441.04(0.86-1.26)0.6551(0.78-1.27)0.9991.1(0.81-1.49)0.54
rs266089A/G0.190.160.2011.23(1.00-1.51)0.0461.46(1.11-1.91)0.0060.99(0.72-1.36)0.938
rs197452T/C0.1160.1160.8521.00(0.78-1.27)0.970.96(0.7-1.31)0.7811.05(0.72-1.53)0.808
rs2839693T/C0.1680.1450.6421.19(0.96-1.47)0.1131.44(1.09-1.89)0.010.89(0.63-1.26)0.529
rs10793538T/A0.0460.0680.1190.669(0.47-0.93)0.0160.77(0.5-1.2)0.2490.52(0.3-0.92)0.019

p <0.01, statistical significance for HWE

p <0.05, statistical significance.

p <0.01, statistical significance for HWE p <0.05, statistical significance. We further explored the relationship between CXCL12 gene and CAD in four genetic models (genotype, dominant, recessive and log-additive model) by unconditional logistic regression (Table 4). Results show that the odds of having CAD would be 1.30-fold (95%CI: 1.30-1.65, p=0.028) with GA-AA genotype, compared with the subjects with the homozygous GG genotype in the dominant model. A log-additive model revealed a potential association with CAD (OR = 0.67, 95%CI: 0.48-0.94, p= 0.018). But after adjusting by gender and age, we found no association between the SNPs and CAD.
Table 4

Associations between CXCL12 SNPs and CAD

SNPModelGenotypecontrolcaseCrude analysisadjusted by age and gender
OR (95% CI)p-valueOR (95% CI)p-value
rs266089CodominantG/G487 (71.2%)391 (65.5%)10.08610.18
G/A175 (25.6%)185 (31%)1.32 (1.03-1.68)1.31(0.97-1.75)
A/A22 (3.2%)21 (3.5%)1.19 (0.64-2.19)0.91(0.43-1.94)
DominantG/G487 (71.2%)391 (65.5%)10.02810.11
G/A-A/A197 (28.8%)206 (34.5%)1.30 (1.03-1.65)1.26(0.95-1.67)
RecessiveG/G-G/A662 (96.8%)576 (96.5%)10.7710.65
A/A22 (3.2%)21 (3.5%)1.10 (0.60-2.02)0.84(0.40-1.78)
Log-additive---------1.23 (1.00-1.50)0.0481.17(0.91-1.49)0.22
rs10793538CodominantA/A594 (87.2%)544 (91.1%)10.0610.61
T/A81 (11.9%)51 (8.5%)0.69 (0.48-0.99)0.91(0.58-1.41)
T/T6 (0.9%)2 (0.3%)0.36 (0.07-1.81)0.40(0.05-3.21)
DominantA/A594 (87.2%)544 (91.1%)10.02510.54
T/A-T/T87 (12.8%)53 (8.9%)0.67 (0.46-0.95)0.87(0.57-1.35)
RecessiveA/A-T/A675 (99.1%)595 (99.7%)10.210.37
T/T6 (0.9%)2 (0.3%)0.38 (0.08-1.88)0.40(0.05-3.25)
Log-additive---------0.67 (0.48-0.94)0.0180.86(0.57-1.28)0.45

p <0.05, statistical significance.

p <0.05, statistical significance. Stratified according to gender, we found that under the dominant model rs266089 “GA-AA” genotype and rs2839693 “CT-TT” genotype increased the risk of CAD in men (rs266089: OR=1.54, 95%CI: 1.13-2.10, p=0.006; rs2839693: OR=1.51, 95%CI: 1.10-2.07, p=0.010) (Table 5). While in the women, rs1065297 and rs10793538 decreased the CAD risk under the log-additive model (rs1065297: OR=0.52, 95%CI: 0.30-0.91, p=0.021; rs10793538: OR=0.53, 95%CI: 0.31-0.93, p=0.027) (Table 5).
Table 5

The relationship between CXCL12 genetic polymorphism and CAD was analyzed according to the gender stratification

SNPModelGenotypecontrolcaseCrude analysisadjusted by age and gender
OR (95% CI)p-valueOR (95% CI)p-value
Malers266089GenotypeGG28424210.02210.054
GA921191.52(1.10-2.10)0.0111.57(1.09-2.28)0.017
AA10181.76(0.78-3.99)0.1761.34(0.51-3.50)0.551
DominantGG28424210.00610.016
GA-AA1021371.54(1.13-2.10)1.55(1.08-2.21)
RecessiveGG-GA37636110.28210.733
AA10181.56(0.69-3.52)1.18(0.45-3.07)
Log-additive---------1.45(1.11-1.19)0.0071.41(1.04-1.93)0.029
rs2839693GenotypeCC29225210.03610.19
CT861111.50(1.01-2.08)0.0161.40(0.96-2.04)
TT9131.67(0.70-3.98)0.2441.45(0.52-4.08)0.477
DominantCC29225210.0110.069
CT-TT951241.51(1.10-2.07)1.40(0.97-2.02)
RecessiveCC-CT37836310.35310.584
TT9131.50(0.64-3.56)1.33(0.48-3.73)
Log-additive---------1.42 (1.08-1.87)0.0121.33(0.97-1.83)0.079
Femalers1065297GenotypeAA25720310.1710.614
AG40180.57(0.32-1.02)0.060.68(0.32-1.45)0.323
GG30////
DominantAA25720310.03210.244
AG-GG43180.53(0.3-0.95)0.64(0.3-1.35)
RecessiveAA-AG2972211/1/
GG30//
Log-additive---------0.52(0.3-0.91)0.0210.63(0.31-1.28)0.199
rs10793538GenotypeAA25820310.20610.787
AT39180.59(0.33-1.06)0.0750.77(0.36-1.63)0.489
TT30////
DominantAA25820310.04110.379
AT-TT42180.54(0.3-0.97)0.72(0.34-1.51)
RecessiveAA-AT2972211/1/
TT30//
Log-additive---------0.53(0.31-0.93)0.0270.69(0.34-1.4)0.307

p <0.05, statistical significance.

p <0.05, statistical significance. Stratified according to age, we found that under the log-additive model, rs197452 decreased the risk of CAD in less than 50 years old group (rs197452: OR=0.63, 95%CI: 0.39-1.00, p=0.042). While in more than 50 years old group, we did not find significant results (Table 6).
Table 6

The relationship between CXCL12 genetic polymorphism and CAD was analyzed according to the age stratification

SNPModelGenotypecontrolcaseCrude analysisadjusted by age and gender
OR (95% CI)p-valueOR (95% CI)p-value
<55rs197452CodominantC/C393 (78.9%)141 (85.5%)10.07310.081
C/T101 (20.3%)24 (14.6%)0.66 (0.41-1.08)0.68 (0.42-1.11)
T/T4 (0.8%)0 (0%)0.00 (0.00-NA)0.00 (0.00-NA)
DominantC/C393 (78.9%)141 (85.5%)10.0610.077
C/T-T/T105 (21.1%)24 (14.6%)0.64 (0.39-1.03)0.65 (0.40-1.06)
RecessiveC/C-C/T494 (99.2%)165 (100%)10.1310.11
T/T4 (0.8%)0 (0%)0.00 (0.00-NA)0.00 (0.00-NA)
Log-additive---------0.63 (0.39-1.00)0.0420.64 (0.40-1.02)0.053
≥55rs197452CodominantC/C141 (75.4%)328 (75.9%)10.9710.96
C/T42 (22.5%)94 (21.8%)0.96 (0.64-1.46)0.95 (0.63-1.44)
T/T4 (2.1%)10 (2.3%)1.07 (0.33-3.48)1.09 (0.33-3.53)
DominantC/C141 (75.4%)328 (75.9%)10.8910.86
C/T-T/T46 (24.6%)104 (24.1%)0.97 (0.65-1.45)0.97 (0.65-1.44)
RecessiveC/C-C/T183 (97.9%)422 (97.7%)10.8910.88
T/T4 (2.1%)10 (2.3%)1.08 (0.34-3.50)1.10 (0.34-3.55)
Log-additive---------0.99 (0.69-1.40)0.940.98 (0.69-1.39)0.92

p <0.05, statistical significance.

p <0.05, statistical significance. Only one block was detected in the analysis using haploview software. The block consisted of rs1801157, rs266089, rs197452 and rs2839693 (Figure 1). The result of the association between CXCL12 haplotype and CAD risk were listed in Table 7. We found that haplotype “TGCC” in the block increased CAD risk (OR=1.26, 95%CI: 1.00-1.58, p=0.046) (Table 7). While there was no statistical valid after adjusting age and sex.
Figure 1

Haplotype block for the SNPs of CXCL12

Table 7

CXCL12 haplotype frequencies and their association with CAD

HaplotypeFreqcasecontrolOR (95% CI)p-value
CGCC0.49430.4760.511.00---
TGCC0.21310.2170.211.10 (0.90 - 1.35)0.34
CACT0.15320.1670.1411.26 (1.00 - 1.58)0.046
CGTC0.11580.1160.1161.06 (0.82 - 1.37)0.64
CACC0.02120.0240.0191.29 (0.75 - 2.21)0.36

p <0.05, statistical significance.

p <0.05, statistical significance.

DISCUSSION

It is widely acknowledged that hereditary factors contribute importantly to the risk of CAD and a large amount of genes and SNPs have been identified to be associated with CAD in various races [15, 16]. In the current study, we detected 6 SNPs to identify the relationship between CAD and CXCL12 and found three (rs1065297, rs266089 and rs10793538) significant SNPs. As far as we known, these 3 SNPs were first reported to be associated with CAD risk. GWAS reported that SDF-1 gene (CXCL-12), which located on 10q11.1 and involved in progenitor cell proliferation, traffic, adhesion and regulates cell survival, associated with cardiovascular disease susceptibility. We also found that rs266089 in CXCL12 gene increased the CAD risk in total population and in men; rs2839693 in CXCL12 gene associated with the risk of CAD in men. A study explored the SDF1 SNPs for prognostic impact in patients with cardiovascular disease, found that cardiovascular who were SDF1 rs2839693 and rs266089 minor allele carriers showed a significantly better event-free survival probability compared to homozygote carriers of major allele [17]. Apart from this, an article reported that homozygous genotype of the minor allele of rs2839693, A/A, was shown to be significantly decreased in ITP patients, which suggested a protective role of these genotypes [18]. Published studies have shown that the relationship between rs1801157 and CAD susceptibility exist inconsistent. Some studies suggested that rs1801157 in CXCL12 gene is not associated with the risk of coronary heart disease [19-21]. However, some studies have suggested that CXCL12 gene may affect the risk of coronary heart disease [22-25]. By integrating the results of other studies, meta-analysis showed that the rs1801157 in CXCL12 gene was not associated with the risk of coronary heart disease. In our research, we did not find the relationship between SNP rs1801157 and susceptibility to CAD. But, we found that significant differences in TP concentrations with rs1801157 different genotype. Actually there were some limitations in our study. The sample volume of the case-control study (597 cases and 685 controls) was not relatively large enough. The most defect of our specimen was the mismatching of age and sex. It would still have some random error although in a certain extent though we indeed did some adjustment. The most useful way to solve the question we thought is to take them as independent factors. The main methods of controlling the confounding factors include restrictions on randomization, matching, stratified analysis, multivariate analysis. Due to the age and sex is not match, in the process of statistical analysis, ORs and 95%CIs were computed based on unconditional logistic regression adjusted by age and gender. In addition to, further stratified analysis by sex and age were performed to eliminate the influence of confounding factors. Our findings in the case-control study provide new evidence for the relationship between SNPs and haplotype of CXCL12 with CAD risk. What is more, we found different influence of the SNPs between males and females. It's a pity that we did not clarify the mechanism of how the SNPs affect the risk of CAD but we thought it would be a new research direction in the future.

MATERIALS AND METHODS

Ethics statement

The protocol in this study conformed to the principles of the Declaration of Helsinki and was ratified by the Ethical Committee of the First Affiliated Hospital of Xi’an Jiaotong University Health Science Center, China. Signed informed consent was obtained from each participant.

Study participants

A total of 597 patients were recruited in the department of cardiology in First Affiliated Hospital of Xi’an Jiaotong University from. At least two experienced cardiologists performed the diagnosis of CHD according to American Heart Association guidelines [26]. All patients were confirmed by the obstruction of at least 1 large epicardial coronary artery by atheromatous plaque using coronary angiography (>50% diameter stenosis in at least one of the major coronary arteries). Patients who met the exclusion criteria will be excluded from this study: alcohol abuse, diabetes, a history of smoking, chronic lung disease, xanthelasma, and evidence of noncoronary atherosclerotic disease. We also collected the clinical data of CAD patient, including Serum concentrations of ALT, AST, GGT, TP, GLU, TG, TC, HDL-C, LDL-C, APOA, APOB, Lp(a). Additionally, there were in total 708 relative healthy controls in other departments were involved but 23 were excluded for the defective information or the poor DNA quality. Eventually, 597 case groups and 685 control groups with informed consent were taken into consideration to explore the association between the 6 SNPs and CAD. All the subjects were Chinese Han people and the information was collected by the medical records.

SNP selection and genotyping

We selected candidate SNPs of CXCL12 according to previous published papers which demonstrated association with CAD in other ethnic lines and only MAF>5% in the Hapmap Asian population were valid [17]. Finally, a number of 6 SNPs were chosen for further analysis. Genomic DNA extracted and concentrated were accomplished using GoldMag-Mini Purification Kit (GoldMag Co. Ltd. Xian city, China) and spectrometry (DU530 UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA), respectively. Sequenom MassARRAY RS1000 was applied to genotype the candidate SNPs and subsequently data management and analysis were performed by the Sequenom Typer 4.0 Software [27].

Statistical analysis

For continuous variable, presented as means ± standard deviations (SDs), performed by T-test; for categorical variables performed by Pearson's chi-square test. From variance analysis assess the differences in continuous variables among the subjects with three genotypes of related genes. Hardy-Weinberg equilibrium (HWE) was performed for each SNP in control groups using exact test. The differences in allele and genotype frequencies for each SNP between cases and controls were detected using Pearson Chi-Square (χ2) test [28]. ORs and 95%CIs were computed based on unconditional logistic regression [29]. Further stratified analysis by sex and age were performed to eliminate the influence of confounding factors. The four genetic models, dominant, co-dominant, recessive and log-additive were applied by PLINK software (http://pngu.mgh.harvard.edu/purcell/plink/) to evaluate the association between the SNPs and CAD. Statistical analyses were performed using Microsoft Excel and PLINK software. And two-sided p-values < 0.05 were considered statistically significant.
  29 in total

1.  Genetics of coronary artery disease: focus on genome-wide association studies.

Authors:  Linnea M Baudhuin
Journal:  Am J Transl Res       Date:  2009-03-05       Impact factor: 4.060

Review 2.  Epidemiological studies of CHD and the evolution of preventive cardiology.

Authors:  Nathan D Wong
Journal:  Nat Rev Cardiol       Date:  2014-03-25       Impact factor: 32.419

3.  Response to injury and atherogenesis.

Authors:  R Ross; J Glomset; L Harker
Journal:  Am J Pathol       Date:  1977-03       Impact factor: 4.307

Review 4.  CXCL12: a new player in coronary disease identified through human genetics.

Authors:  Samira S Farouk; Daniel J Rader; Muredach P Reilly; Nehal N Mehta
Journal:  Trends Cardiovasc Med       Date:  2010-08       Impact factor: 6.677

5.  High-throughput informative single nucleotide polymorphism-based typing of Neisseria gonorrhoeae using the Sequenom MassARRAY iPLEX platform.

Authors:  Ella Trembizki; Helen Smith; Monica M Lahra; Marcus Chen; Basil Donovan; Christopher K Fairley; Rebecca Guy; John Kaldor; David Regan; James Ward; Michael D Nissen; Theo P Sloots; David M Whiley
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790

6.  Polymorphism of stromal cell-derived factor-1 selectively upregulates gene expression and is associated with increased susceptibility to coronary artery disease.

Authors:  Xiao-Long Gu; Na Ma; Ding-Cheng Xiang; Jun Huang; Zheng-Hua Dong; Hui-Yan Lei; Ru Ding; Zhi-Hua Gong; Yan-Fei Wen; Jian Qiu; Lan Ma
Journal:  Biochem Biophys Res Commun       Date:  2013-12-19       Impact factor: 3.575

7.  Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease.

Authors:  Stavros Apostolakis; Stavroula Baritaki; Georgios E Kochiadakis; Nikolaos E Igoumenidis; Dimitrios Panutsopulos; Demetrios A Spandidos
Journal:  Thromb Res       Date:  2006-02-09       Impact factor: 3.944

8.  Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.

Authors:  Christopher J L Murray; Ryan M Barber; Kyle J Foreman; Ayse Abbasoglu Ozgoren; Foad Abd-Allah; Semaw F Abera; Victor Aboyans; Jerry P Abraham; Ibrahim Abubakar; Laith J Abu-Raddad; Niveen M Abu-Rmeileh; Tom Achoki; Ilana N Ackerman; Zanfina Ademi; Arsène K Adou; José C Adsuar; Ashkan Afshin; Emilie E Agardh; Sayed Saidul Alam; Deena Alasfoor; Mohammed I Albittar; Miguel A Alegretti; Zewdie A Alemu; Rafael Alfonso-Cristancho; Samia Alhabib; Raghib Ali; François Alla; Peter Allebeck; Mohammad A Almazroa; Ubai Alsharif; Elena Alvarez; Nelson Alvis-Guzman; Azmeraw T Amare; Emmanuel A Ameh; Heresh Amini; Walid Ammar; H Ross Anderson; Benjamin O Anderson; Carl Abelardo T Antonio; Palwasha Anwari; Johan Arnlöv; Valentina S Arsic Arsenijevic; Al Artaman; Rana J Asghar; Reza Assadi; Lydia S Atkins; Marco A Avila; Baffour Awuah; Victoria F Bachman; Alaa Badawi; Maria C Bahit; Kalpana Balakrishnan; Amitava Banerjee; Suzanne L Barker-Collo; Simon Barquera; Lars Barregard; Lope H Barrero; Arindam Basu; Sanjay Basu; Mohammed O Basulaiman; Justin Beardsley; Neeraj Bedi; Ettore Beghi; Tolesa Bekele; Michelle L Bell; Corina Benjet; Derrick A Bennett; Isabela M Bensenor; Habib Benzian; Eduardo Bernabé; Amelia Bertozzi-Villa; Tariku J Beyene; Neeraj Bhala; Ashish Bhalla; Zulfiqar A Bhutta; Kelly Bienhoff; Boris Bikbov; Stan Biryukov; Jed D Blore; Christopher D Blosser; Fiona M Blyth; Megan A Bohensky; Ian W Bolliger; Berrak Bora Başara; Natan M Bornstein; Dipan Bose; Soufiane Boufous; Rupert R A Bourne; Lindsay N Boyers; Michael Brainin; Carol E Brayne; Alexandra Brazinova; Nicholas J K Breitborde; Hermann Brenner; Adam D Briggs; Peter M Brooks; Jonathan C Brown; Traolach S Brugha; Rachelle Buchbinder; Geoffrey C Buckle; Christine M Budke; Anne Bulchis; Andrew G Bulloch; Ismael R Campos-Nonato; Hélène Carabin; Jonathan R Carapetis; Rosario Cárdenas; David O Carpenter; Valeria Caso; Carlos A Castañeda-Orjuela; Ruben E Castro; Ferrán Catalá-López; Fiorella Cavalleri; Alanur Çavlin; Vineet K Chadha; Jung-Chen Chang; Fiona J Charlson; Honglei Chen; Wanqing Chen; Peggy P Chiang; Odgerel Chimed-Ochir; Rajiv Chowdhury; Hanne Christensen; Costas A Christophi; Massimo Cirillo; Matthew M Coates; Luc E Coffeng; Megan S Coggeshall; Valentina Colistro; Samantha M Colquhoun; Graham S Cooke; Cyrus Cooper; Leslie T Cooper; Luis M Coppola; Monica Cortinovis; Michael H Criqui; John A Crump; Lucia Cuevas-Nasu; Hadi Danawi; Lalit Dandona; Rakhi Dandona; Emily Dansereau; Paul I Dargan; Gail Davey; Adrian Davis; Dragos V Davitoiu; Anand Dayama; Diego De Leo; Louisa Degenhardt; Borja Del Pozo-Cruz; Robert P Dellavalle; Kebede Deribe; Sarah Derrett; Don C Des Jarlais; Muluken Dessalegn; Samath D Dharmaratne; Mukesh K Dherani; Cesar Diaz-Torné; Daniel Dicker; Eric L Ding; Klara Dokova; E Ray Dorsey; Tim R Driscoll; Leilei Duan; Herbert C Duber; Beth E Ebel; Karen M Edmond; Yousef M Elshrek; Matthias Endres; Sergey P Ermakov; Holly E Erskine; Babak Eshrati; Alireza Esteghamati; Kara Estep; Emerito Jose A Faraon; Farshad Farzadfar; Derek F Fay; Valery L Feigin; David T Felson; Seyed-Mohammad Fereshtehnejad; Jefferson G Fernandes; Alize J Ferrari; Christina Fitzmaurice; Abraham D Flaxman; Thomas D Fleming; Nataliya Foigt; Mohammad H Forouzanfar; F Gerry R Fowkes; Urbano Fra Paleo; Richard C Franklin; Thomas Fürst; Belinda Gabbe; Lynne Gaffikin; Fortuné G Gankpé; Johanna M Geleijnse; Bradford D Gessner; Peter Gething; Katherine B Gibney; Maurice Giroud; Giorgia Giussani; Hector Gomez Dantes; Philimon Gona; Diego González-Medina; Richard A Gosselin; Carolyn C Gotay; Atsushi Goto; Hebe N Gouda; Nicholas Graetz; Harish C Gugnani; Rahul Gupta; Rajeev Gupta; Reyna A Gutiérrez; Juanita Haagsma; Nima Hafezi-Nejad; Holly Hagan; Yara A Halasa; Randah R Hamadeh; Hannah Hamavid; Mouhanad Hammami; Jamie Hancock; Graeme J Hankey; Gillian M Hansen; Yuantao Hao; Hilda L Harb; Josep Maria Haro; Rasmus Havmoeller; Simon I Hay; Roderick J Hay; Ileana B Heredia-Pi; Kyle R Heuton; Pouria Heydarpour; Hideki Higashi; Martha Hijar; Hans W Hoek; Howard J Hoffman; H Dean Hosgood; Mazeda Hossain; Peter J Hotez; Damian G Hoy; Mohamed Hsairi; Guoqing Hu; Cheng Huang; John J Huang; Abdullatif Husseini; Chantal Huynh; Marissa L Iannarone; Kim M Iburg; Kaire Innos; Manami Inoue; Farhad Islami; Kathryn H Jacobsen; Deborah L Jarvis; Simerjot K Jassal; Sun Ha Jee; Panniyammakal Jeemon; Paul N Jensen; Vivekanand Jha; Guohong Jiang; Ying Jiang; Jost B Jonas; Knud Juel; Haidong Kan; André Karch; Corine K Karema; Chante Karimkhani; Ganesan Karthikeyan; Nicholas J Kassebaum; Anil Kaul; Norito Kawakami; Konstantin Kazanjan; Andrew H Kemp; Andre P Kengne; Andre Keren; Yousef S Khader; Shams Eldin A Khalifa; Ejaz A Khan; Gulfaraz Khan; Young-Ho Khang; Christian Kieling; Daniel Kim; Sungroul Kim; Yunjin Kim; Yohannes Kinfu; Jonas M Kinge; Miia Kivipelto; Luke D Knibbs; Ann Kristin Knudsen; Yoshihiro Kokubo; Soewarta Kosen; Sanjay Krishnaswami; Barthelemy Kuate Defo; Burcu Kucuk Bicer; Ernst J Kuipers; Chanda Kulkarni; Veena S Kulkarni; G Anil Kumar; Hmwe H Kyu; Taavi Lai; Ratilal Lalloo; Tea Lallukka; Hilton Lam; Qing Lan; Van C Lansingh; Anders Larsson; Alicia E B Lawrynowicz; Janet L Leasher; James Leigh; Ricky Leung; Carly E Levitz; Bin Li; Yichong Li; Yongmei Li; Stephen S Lim; Maggie Lind; Steven E Lipshultz; Shiwei Liu; Yang Liu; Belinda K Lloyd; Katherine T Lofgren; Giancarlo Logroscino; Katharine J Looker; Joannie Lortet-Tieulent; Paulo A Lotufo; Rafael Lozano; Robyn M Lucas; Raimundas Lunevicius; Ronan A Lyons; Stefan Ma; Michael F Macintyre; Mark T Mackay; Marek Majdan; Reza Malekzadeh; Wagner Marcenes; David J Margolis; Christopher Margono; Melvin B Marzan; Joseph R Masci; Mohammad T Mashal; Richard Matzopoulos; Bongani M Mayosi; Tasara T Mazorodze; Neil W Mcgill; John J Mcgrath; Martin Mckee; Abigail Mclain; Peter A Meaney; Catalina Medina; Man Mohan Mehndiratta; Wubegzier Mekonnen; Yohannes A Melaku; Michele Meltzer; Ziad A Memish; George A Mensah; Atte Meretoja; Francis A Mhimbira; Renata Micha; Ted R Miller; Edward J Mills; Philip B Mitchell; Charles N Mock; Norlinah Mohamed Ibrahim; Karzan A Mohammad; Ali H Mokdad; Glen L D Mola; Lorenzo Monasta; Julio C Montañez Hernandez; Marcella Montico; Thomas J Montine; Meghan D Mooney; Ami R Moore; Maziar Moradi-Lakeh; Andrew E Moran; Rintaro Mori; Joanna Moschandreas; Wilkister N Moturi; Madeline L Moyer; Dariush Mozaffarian; William T Msemburi; Ulrich O Mueller; Mitsuru Mukaigawara; Erin C Mullany; Michele E Murdoch; Joseph Murray; Kinnari S Murthy; Mohsen Naghavi; Aliya Naheed; Kovin S Naidoo; Luigi Naldi; Devina Nand; Vinay Nangia; K M Venkat Narayan; Chakib Nejjari; Sudan P Neupane; Charles R Newton; Marie Ng; Frida N Ngalesoni; Grant Nguyen; Muhammad I Nisar; Sandra Nolte; Ole F Norheim; Rosana E Norman; Bo Norrving; Luke Nyakarahuka; In-Hwan Oh; Takayoshi Ohkubo; Summer L Ohno; Bolajoko O Olusanya; John Nelson Opio; Katrina Ortblad; Alberto Ortiz; Amanda W Pain; Jeyaraj D Pandian; Carlo Irwin A Panelo; Christina Papachristou; Eun-Kee Park; Jae-Hyun Park; Scott B Patten; George C Patton; Vinod K Paul; Boris I Pavlin; Neil Pearce; David M Pereira; Rogelio Perez-Padilla; Fernando Perez-Ruiz; Norberto Perico; Aslam Pervaiz; Konrad Pesudovs; Carrie B Peterson; Max Petzold; Michael R Phillips; Bryan K Phillips; David E Phillips; Frédéric B Piel; Dietrich Plass; Dan Poenaru; Suzanne Polinder; Daniel Pope; Svetlana Popova; Richie G Poulton; Farshad Pourmalek; Dorairaj Prabhakaran; Noela M Prasad; Rachel L Pullan; Dima M Qato; D Alex Quistberg; Anwar Rafay; Kazem Rahimi; Sajjad U Rahman; Murugesan Raju; Saleem M Rana; Homie Razavi; K Srinath Reddy; Amany Refaat; Giuseppe Remuzzi; Serge Resnikoff; Antonio L Ribeiro; Lee Richardson; Jan Hendrik Richardus; D Allen Roberts; David Rojas-Rueda; Luca Ronfani; Gregory A Roth; Dietrich Rothenbacher; David H Rothstein; Jane T Rowley; Nobhojit Roy; George M Ruhago; Mohammad Y Saeedi; Sukanta Saha; Mohammad Ali Sahraian; Uchechukwu K A Sampson; Juan R Sanabria; Logan Sandar; Itamar S Santos; Maheswar Satpathy; Monika Sawhney; Peter Scarborough; Ione J Schneider; Ben Schöttker; Austin E Schumacher; David C Schwebel; James G Scott; Soraya Seedat; Sadaf G Sepanlou; Peter T Serina; Edson E Servan-Mori; Katya A Shackelford; Amira Shaheen; Saeid Shahraz; Teresa Shamah Levy; Siyi Shangguan; Jun She; Sara Sheikhbahaei; Peilin Shi; Kenji Shibuya; Yukito Shinohara; Rahman Shiri; Kawkab Shishani; Ivy Shiue; Mark G Shrime; Inga D Sigfusdottir; Donald H Silberberg; Edgar P Simard; Shireen Sindi; Abhishek Singh; Jasvinder A Singh; Lavanya Singh; Vegard Skirbekk; Erica Leigh Slepak; Karen Sliwa; Samir Soneji; Kjetil Søreide; Sergey Soshnikov; Luciano A Sposato; Chandrashekhar T Sreeramareddy; Jeffrey D Stanaway; Vasiliki Stathopoulou; Dan J Stein; Murray B Stein; Caitlyn Steiner; Timothy J Steiner; Antony Stevens; Andrea Stewart; Lars J Stovner; Konstantinos Stroumpoulis; Bruno F Sunguya; Soumya Swaminathan; Mamta Swaroop; Bryan L Sykes; Karen M Tabb; Ken Takahashi; Nikhil Tandon; David Tanne; Marcel Tanner; Mohammad Tavakkoli; Hugh R Taylor; Braden J Te Ao; Fabrizio Tediosi; Awoke M Temesgen; Tara Templin; Margreet Ten Have; Eric Y Tenkorang; Abdullah S Terkawi; Blake Thomson; Andrew L Thorne-Lyman; Amanda G Thrift; George D Thurston; Taavi Tillmann; Marcello Tonelli; Fotis Topouzis; Hideaki Toyoshima; Jefferson Traebert; Bach X Tran; Matias Trillini; Thomas Truelsen; Miltiadis Tsilimbaris; Emin M Tuzcu; Uche S Uchendu; Kingsley N Ukwaja; Eduardo A Undurraga; Selen B Uzun; Wim H Van Brakel; Steven Van De Vijver; Coen H van Gool; Jim Van Os; Tommi J Vasankari; N Venketasubramanian; Francesco S Violante; Vasiliy V Vlassov; Stein Emil Vollset; Gregory R Wagner; Joseph Wagner; Stephen G Waller; Xia Wan; Haidong Wang; Jianli Wang; Linhong Wang; Tati S Warouw; Scott Weichenthal; Elisabete Weiderpass; Robert G Weintraub; Wang Wenzhi; Andrea Werdecker; Ronny Westerman; Harvey A Whiteford; James D Wilkinson; Thomas N Williams; Charles D Wolfe; Timothy M Wolock; Anthony D Woolf; Sarah Wulf; Brittany Wurtz; Gelin Xu; Lijing L Yan; Yuichiro Yano; Pengpeng Ye; Gökalp K Yentür; Paul Yip; Naohiro Yonemoto; Seok-Jun Yoon; Mustafa Z Younis; Chuanhua Yu; Maysaa E Zaki; Yong Zhao; Yingfeng Zheng; David Zonies; Xiaonong Zou; Joshua A Salomon; Alan D Lopez; Theo Vos
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321

9.  Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease.

Authors:  Jaana A Hartiala; W H Wilson Tang; Zeneng Wang; Amanda L Crow; Alexandre F R Stewart; Robert Roberts; Ruth McPherson; Jeanette Erdmann; Christina Willenborg; Stanley L Hazen; Hooman Allayee
Journal:  Nat Commun       Date:  2016-01-29       Impact factor: 14.919

Review 10.  Genomics era and complex disorders: Implications of GWAS with special reference to coronary artery disease, type 2 diabetes mellitus, and cancers.

Authors:  R Pranavchand; B M Reddy
Journal:  J Postgrad Med       Date:  2016 Jul-Sep       Impact factor: 1.476

View more
  3 in total

Review 1.  Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review.

Authors:  Cristiano Fava; Martina Montagnana
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

2.  Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population.

Authors:  Khalid Khalaf Alharbi; May Salem Alnbaheen; Fawiziah Khalaf Alharbi; Rana M Hasanato; Imran Ali Khan
Journal:  Ann Saudi Med       Date:  2017 Nov-Dec       Impact factor: 1.526

3.  Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study.

Authors:  Shuai Lin; Yi Zheng; Meng Wang; Linghui Zhou; Yuyao Zhu; Yujiao Deng; Ying Wu; Dai Zhang; Na Li; Huafeng Kang; Zhijun Dai
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.